MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2026 International Congress

    Bridging the Genomic Gap: Ancestry-Aware Polygenic Risk and Variant Discovery in African Parkinson’s Disease Cohorts

    B. Adebisi (Osogbo, Nigeria)

    Objective: This study evaluates the shift from Euro-centric data to a diversified landscape. We aim to quantify the performance of European-derived Polygenic Risk Scores (PRS)…
  • 2026 International Congress

    Translational Target Engagement of HER-096 Demonstrates Concordant Proteostasis and Mitochondrial Modulation in Preclinical Models and Patients with Parkinson’s Disease

    K. Holmström, A. Ludwig, N. Kulesskaya, A. Domanska, K. Jääskeläinen, C. Videbaek, H. Huttunen (Espoo, Finland)

    Objective: To evaluate translational target engagement of HER-096, a CDNF-derived peptidomimetic, in preclinical models of Parkinson’s disease (PD) and in a Phase 1b clinical study…
  • 2026 International Congress

    12-week Aerobic Interval Training Induces Hemisphere-Specific Neuroprotection in Parkinson’s Disease: A Multimodal MRI, [18F]Fluorodopa PET/CT and BDNF Study

    K. Lorek, B. Kossowski, A. Marchewka, M. Chalimoniuk, J. Langfort, J. Mączewska, L. Królicki, K. Markowska, S. Budrewicz, M. Koszewicz, Z. Wroński, J. Marusiak (Wroclaw, Poland)

    Objective: To investigate whether a 12-week aerobic interval training (AIT) can preserve subcortical brain structures in early Parkinson’s disease (PD) and whether these effects are…
  • 2026 International Congress

    Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’

    B. Ribba, T. Nikolcheva, P. Pierrillas, C. Diack, A. Monnet, B. Ricci, M. May, G. Pagano, G. Kerchner, P. Brundin (Basel, Switzerland)

    Objective: Evaluate the long-term effectiveness of potential disease-modifying treatments (DMTs) in Parkinson’s disease (PD) using a modelling-based virtual comparator and explore patient-relevant benefits through the…
  • 2026 International Congress

    The Emerging Landscape of Genotype-Stratified Clinical Trials in Parkinson’s Disease and Atypical Parkinsonian Disorders

    YY. Beh, SY. Lim, AM. Abdul Sahak, L. Lange, K. Brolin, A. Noyce, M. Nalls, A. Singleton, H. Morris, AH. Tan (Kuala Lumpur, Malaysia)

    Objective: To characterize the landscape of genotype-stratified clinical trials in Parkinson’s disease (PD) and atypical parkinsonian disorders (APD), including therapeutic targets, geographic representation, and trial…
  • 2026 International Congress

    NLRP3 Inhibition in Early-Stage Parkinson’s disease: Results of a Phase Ib Study

    G. Pagano, B. Zinnhardt, N. Shariati, B. Ricci, M. Tagliati, A. Noyce, B. Bloem, H. Sarva, R. Kumar, K. Marek, K. Brockmann, T. Simuni, D. Standaert, N. Pavese, M. Politis, N. Milani Muelhardt, G. Kerchner, L. Kulic, A. Bonni (London, United Kingdom)

    Objective: To evaluate the effect of selnoflast, an NLRP3 inhibitor, in persons with early-stage Parkinson’s disease (PD). Background: Damage-associated molecular patterns and pathological alpha-synuclein from damaged or…
  • 2026 International Congress

    Exploring a Milestone-Based Approach as an Outcome Measure for Disease-Modifying Parkinson Disease Trials

    C. Gonzalez-Robles, M. Burnell, A. Schrag, R. Weil, G. Mills, ML. Zeissler, J. Carpenter, S. Gandhi, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To replicate a composite milestone(CM) approach in a range of Parkinson Disease(PD) studies(observational, clinical trials) over a long time period(up to 12 years). To…
  • 2026 International Congress

    Assessing an inclusive online lifestyle-based intervention program that supports British Columbians living with chronic neurological conditions, their care partners and healthy agers

    A. Hashimoto, S-A. Stelling, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To evaluate the implementation, feasibility, and perceived benefits of the BC Brain Wellness Program (BCBWP), an interdisciplinary lifestyle-based intervention designed to support the quality of…
  • 2026 International Congress

    Patient-Defined Disease Progression in Parkinson Disease: Towards Patient-Relevant Outcome Measures

    C. Gonzalez-Robles, A. Schrag, R. Weil, M. Burnell, G. Mills, ML. Zeissler, J. Carpenter, S. Gandhi, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To carry out a survey on a representative sample of people with Parkinson’s (PwP) about their lived experience of a comprehensive list of Parkinson…
  • 2026 International Congress

    Move-Brain-PD: a Randomized Multicenter Protocol of Remotely Monitored Home-based Aerobic Exercise for Parkinson’s Disease Patients with Mild Cognitive Impairment

    AT. Cimmino, G. Di Lazzaro, D. Genovese, VL. Marian, IF. Ivan, RM. Scheytt, AR. Bentivoglio, TF. Outeiro, C. Falup-Pecurariu, P. Calabresi (Rome, Italy)

    Objective: To describe the rationale and design of Move-Brain-PD, a randomized multicenter study evaluating whether remotely monitored home-based aerobic exercise improves cognition and motor symptoms…
  • 1
  • 2
  • 3
  • …
  • 22
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley